These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 21333731)
1. Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte. Wang X; Wang Z; Liu JZ; Hu JX; Chen HL; Li WL; Hai CX Toxicol In Vitro; 2011 Jun; 25(4):839-47. PubMed ID: 21333731 [TBL] [Abstract][Full Text] [Related]
3. Protective effect of the peroxisome proliferator-activated receptor (PPAR)-γ, ligand rosiglitazone on tert-butyl hydroperoxide-induced QZG cell injury. Li WL; Liang X; Wang X; Zhang XD; Liu R; Zhang W; Chen HL; Qin XJ; Bai H; Hai CX Exp Toxicol Pathol; 2011 Sep; 63(6):527-33. PubMed ID: 20510595 [TBL] [Abstract][Full Text] [Related]
4. Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells. Meshkani R; Sadeghi A; Taheripak G; Zarghooni M; Gerayesh-Nejad S; Bakhtiyari S Cell Biochem Funct; 2014 Dec; 32(8):683-91. PubMed ID: 25431031 [TBL] [Abstract][Full Text] [Related]
5. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia. Berthiaume M; Laplante M; Tchernof A; Deshaies Y Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631 [TBL] [Abstract][Full Text] [Related]
6. Apoptotic action of peroxisome proliferator-activated receptor-gamma activation in human non small-cell lung cancer is mediated via proline oxidase-induced reactive oxygen species formation. Kim KY; Ahn JH; Cheon HG Mol Pharmacol; 2007 Sep; 72(3):674-85. PubMed ID: 17535976 [TBL] [Abstract][Full Text] [Related]
7. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Yuan Y; Zhang A; Huang S; Ding G; Chen R Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490 [TBL] [Abstract][Full Text] [Related]
9. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue. Joosen AM; Bakker AH; Kersten S; Westerterp KR Br J Nutr; 2008 Mar; 99(3):487-93. PubMed ID: 18177513 [TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Sommer M; Wolf G Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750 [TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Tencer L; Burgermeister E; Ebert MP; Liscovitch M Anticancer Res; 2008; 28(2A):895-906. PubMed ID: 18507034 [TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Díaz-Delfín J; Morales M; Caelles C Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798 [TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Sánchez-Hidalgo M; Martín AR; Villegas I; de la Lastra CA Eur J Pharmacol; 2007 May; 562(3):247-58. PubMed ID: 17343846 [TBL] [Abstract][Full Text] [Related]
14. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. Sotiropoulos KB; Clermont A; Yasuda Y; Rask-Madsen C; Mastumoto M; Takahashi J; Della Vecchia K; Kondo T; Aiello LP; King GL FASEB J; 2006 Jun; 20(8):1203-5. PubMed ID: 16672634 [TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone via PPARγ-dependent suppression of oxidative stress attenuates endothelial dysfunction in rats fed homocysteine thiolactone. Yang XH; Li P; Yin YL; Tu JH; Dai W; Liu LY; Wang SX J Cell Mol Med; 2015 Apr; 19(4):826-35. PubMed ID: 25656735 [TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells. Whiteside C; Wang H; Xia L; Munk S; Goldberg HJ; Fantus IG Exp Diabetes Res; 2009; 2009():910783. PubMed ID: 19609456 [TBL] [Abstract][Full Text] [Related]
17. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats. El Midaoui A; Wu L; Wang R; de Champlain J Am J Hypertens; 2006 Apr; 19(4):407-12. PubMed ID: 16580578 [TBL] [Abstract][Full Text] [Related]
18. Protective role of arjunolic acid in response to streptozotocin-induced type-I diabetes via the mitochondrial dependent and independent pathways. Manna P; Sinha M; Sil PC Toxicology; 2009 Mar; 257(1-2):53-63. PubMed ID: 19133311 [TBL] [Abstract][Full Text] [Related]
19. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418 [TBL] [Abstract][Full Text] [Related]
20. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3'-kinase-dependent pathway. Lin CY; Gurlo T; Haataja L; Hsueh WA; Butler PC J Clin Endocrinol Metab; 2005 Dec; 90(12):6678-86. PubMed ID: 16204373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]